急性心力衰竭发作后的迪戈辛启动及其与出院后结果的关联:国际多中心分析
Òscar Miró1,2,3, Enrique Martín Mojarro4, Gabrielle Huré5,6
1Emergency Department, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain. omiro@clinic.cat.
Internal and emergency medicine
|August 22, 2024
概括
在急性心力衰竭 (AHF) 后使用digoxin与特定的患者特征有关,如心房动 (AF) 和减少射出分数. 然而,在AHF后启动迪戈辛并没有改善这项研究中90天的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 迪戈辛经常用于急性心力衰竭 (AHF),特别是在同时患有心房动 (AF) 的患者中.
- 关于最佳的患者选择,时间和迪戈辛启动对AHF患者结果的影响,存在有限的共识.
- 本研究探讨了影响迪戈辛启动的因素及其与AHF患者短期不良事件的关联.
研究的目的:
- 为了确定患者特征和与AHF发作后迪戈辛启动相关的临床因素.
- 评估狄戈辛启动是否影响90天的综合不良事件 (全因死亡或AHF住院).
主要方法:
- 对西班牙和瑞士联合数据库的分析,这些数据库是以前没有服用过狄戈辛的AHF患者.
- 患者根据在出院时接受的狄戈辛被分类.
- 研究了狄戈辛启动与23个共同变量之间的关联,包括并发症和慢性治疗,以及90天的不良事件.
主要成果:
- 在13105名AHF患者中,3.7%的患者观察到滴氧素的启动,在西班牙队列中更频繁.
- 相关因素包括AF,女性性别,左心室喷射率降低 (LVEF<50%),以及没有糖尿病 (DM) 或慢性病 (CKD).
- 迪戈辛的启动与90天的不良事件没有显著关联,在CKD和队列起源方面注意到了显著的相互作用.
结论:
- 在AHF后的迪戈辛启动与特定的患者个人资料有关,包括AF和减少的LVEF,并且根据地理队列而异.
- 尽管存在这些关联,但狄戈辛的启动并没有在此之前未服用狄戈辛的AHF人群中对90天的不良结果产生显著影响.
- 可能需要进一步的研究来澄清狄戈辛在特定AHF患者亚组中的作用,考虑到与CKD等并发症的潜在相互作用.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
936
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
936
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405